Injectable body temperature responsive hydrogel for encephalitis treatment via sustained release of nano-anti-inflammatory agents

Skull defects are common in the clinical practice of neurosurgery, and they are easily complicated by encephalitis, which seriously threatens the life and health safety of patients. The treatment of encephalitis is not only to save the patient but also to benefit the society. Based on the advantages of injectable hydrogels such as minimally invasive surgery, self-adaptation to irregularly shaped defects, and easy loading and delivery of nanomedicines, an injectable hydrogel that can be crosslinked in situ at the ambient temperature of the brain for the treatment of encephalitis caused by cranial defects is developed. The hydrogel is uniformly loaded with nanodrugs formed by cationic liposomes and small molecule drugs dexmedetomidine hydrochloride (DEX-HCl), which can directly act on the meninges to achieve sustained release delivery of anti-inflammatory nanodrug preparations and achieve the goal of long-term anti-inflammation at cranial defects. This is the first time that DEX-HCl has been applied within this therapeutic system, which is innovative. Furthermore, this study is expected to alleviate the long-term suffering of patients, improve the clinical medication strategies for antiinflammatory treatment, promote the development of new materials for cranial defect repair, and expedite the translation of research outcomes into clinical practice.